Icahn School of Medicine at Mount Sinai Awarded More Than $5 Million from NIH To Study Spasmodic Dysphonia
Dr. Simonyan's laboratory at Mount Sinai is studying the causes and disease pathology to address an unmet need for treatments in people with this underdiagnosed disorder
Kristina Simonyan, MD, PhD, from the Icahn School of Medicine at Mount Sinai, has received more than $5 million from the National Institutes of Health (NIH) to study spasmodic dysphonia (SD), a neurological disorder characterized by vocal cord spasms. Dr. Simonyan is studying the causes and disease pathology of SD in hopes of identifying new drug targets to address a significant unmet need for treatments in people with this debilitating disorder.
To develop new treatment options for patients with SD who failed available options, Dr. Simonyan’s team is examining the central mechanisms of action of a novel oral medication, sodium oxybate, which is FDA-approved for narcolepsy. Anecdotally, about 20 percent of SD patients have positive effects of alcohol on their voice symptoms. Research shows that patients whose condition improves by drinking alcohol benefit from taking sodium oxybate because it acts on the brain through the same mechanisms as alcohol.
SD develops spontaneously in midlife and progresses to become a chronic condition. It is characterized by interruptions in speech and can cause the voice to break up, sound strained or breathy, but without any damage to the vocal cords or throat. The causes and disease biology of SD are unknown, and the treatment is limited to symptomatic management of the disorder, such as with repeated injections of botulinum toxin into the affected muscles of the voice box, which does not work for all patients. The injections also have side effects that cause the person to lose their voice altogether for some time before they see improvement.
“Spasmodic dysphonia can have a terrible impact on quality of life, often causing emotional stress, social embarrassment, isolation, and even loss of employment,” said Dr. Simonyan, who is an Associate Professor of Neurology and Otolaryngology at Mount Sinai. “A better understanding of the disease and how to treat it is desperately needed to help us find a cure, rather than only treating the symptoms of it.”
By combining high-resolution brain imaging and next-generation whole exome sequencing, Dr. Simonyan’s team is examining genetically modified differences in brain abnormalities in 240 patients with different types of SD. The team also is evaluating how people with SD perceive and process different sensory stimulations, such as flashing lights, smells and sounds, and how they integrate (or fail to integrate) this information with motor control of their speech production. By understanding the interactions between brain organization, genetic susceptibility and risk factors, sensory input and motor output, the researchers hope to identify diagnostic biomarkers of this disorder. Biomarkers are needed to prevent misdiagnoses, and for detection and evaluation of SD patients as well as screening of people at risk for SD development.
“The use of advanced neuroimaging methodologies together with extensive analyses of brain functional and structural organization in these patients is anticipated to yield novel results, which will be critical for the establishment of criteria for improved clinical management of this disorder,” said Dr. Simonyan.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2025-2026.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
